Truist analyst Gregory Renza initiated coverage of CG Oncology (CGON) with a Buy rating and $62 price target The firm views Creto’s high complete response rates, favorable tolerability, and differentiated durability as key attributes that could support robust market positioning for the company, the analyst tells investors in a research note. The potential expansion into intermediate-risk/IR NMIBC, or Non-Muscle Invasive Bladder Cancer, and additional high-risk settings represent a strategic approach that could broaden Creto’s commercial opportunity, given the ongoing BCG – Bacillus Calmette Guerin – shortage, Truist added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGON:
- CG Oncology price target raised to $61 from $53 at RBC Capital
- CG Oncology, Inc.: Promising Future with Creto’s Accelerated Approval Path and Market Differentiation
- Strategic Advancements and Risk Mitigation Drive Buy Rating for CG Oncology, Inc.
- CG Oncology Advances Bladder Cancer Therapy Development
- CG Oncology Appoints Jim DeTore as Interim CFO